Department of Health and Human Services
Participating Organizations
National Institutes of Health (NIH), (http://www.nih.gov)
Components of Participating Organizations
National Cancer Institute (NCI), (http://www.nci.nih.gov)
Title: Pilot Studies in Pancreatic Cancer
Announcement Type
New
Update: The following update relating to this announcement has been issued:
Program Announcement (PA) Number: PA-05-116
Catalog of Federal Domestic Assistance Number(s)
93.393
Key Dates
Release Date: May 26, 2005
Letter of Intent Receipt Dates: http://grants.nih.gov/grants/funding/submissionschedule.htm
Application Receipt Dates: http://grants.nih.gov/grants/funding/submissionschedule.htm
Peer Review Dates: http://grants.nih.gov/grants/funding/submissionschedule.htm
Council Review Dates: http://grants.nih.gov/grants/funding/submissionschedule.htm
Earliest Anticipated Start Date: http://grants.nih.gov/grants/funding/submissionschedule.htm
Additional Information To Be Available Date (URL Activation Date): Not Applicable
Expiration Date for R03 and R21 Non-AIDS Applications: March 2, 2006
Expiration Date for R03 and R21 AIDS and AIDS-Related Applications: May 2, 2006
Due Dates for E.O. 12372
Not Applicable
Additional Overview Content
Executive Summary
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2. Cost Sharing or Matching
3. Other - Special Eligibility Criteria
Section IV. Application and Submission Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Receipt, Review and Anticipated Start Dates
1. Letter of Intent
B. Sending an Application to the NIH
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Sharing Research Data
D. Sharing Research Resources
3. Anticipated Announcement and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and National Policy Requirements
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
Section VIII. Other Information - Required Federal Citations
Part II - Full Text of AnnouncementThe Division of Cancer Control and Population Sciences (DCCPS), Division of Cancer Biology (DCB), Division of Cancer Prevention (DCP), and Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) invite Exploratory Grant (R21) and Small Grant (R03) applications relating to the biology, etiology, detection, prevention, and treatment of pancreatic cancer. These are short-term awards intended to provide support for pilot projects, testing of new techniques, and/or development of innovative projects that could provide a basis for more extended research.
1. Research Objectives
According to a recent estimate, there would be 31,860 new cases of pancreatic cancer and 31,270 deaths from this disease in 2004. Pancreatic cancer is a highly lethal disease marked by pain, anorexia, sleep problems, and weight loss. Most pancreatic cancers are adenocarcinomas, arising in the pancreatic ductal system, and have the worst prognosis of all the major malignancies. Due to its aggressiveness and our inability to detect pancreatic cancer at an early stage, the disease is often far advanced in patients by the time the diagnosis is established. The 5-year relative survival rate for all stages is approximately 4 percent. Conventional treatment approaches such as chemotherapy, radiation surgery, or combinations of these modalities have had little impact on the course of this disease in patients. It is clear that a better understanding of the etiology, and biology, of pancreatic cancer is urgently needed to effectively diagnose, prevent, and treat this malignancy.
The incidence of pancreatic cancer varies with age, gender, and race. Whereas pancreatic cancer is rare in people under age 25, and quite uncommon in those under age 45, over 70 percent of pancreatic cancer cases occur in people 60-80 years old. Although pancreatic cancer is more prevalent in industrialized countries, the highest incidence in men has been reported among the New Zealand Maoris. In the U.S., incidence and mortality rates for pancreatic cancer are 50 percent higher in African Americans than in whites. Rates for Native Hawaiians are slightly higher than those in whites, whereas the rates for Hispanics and Asian Americans are generally lower. Due to the short lifespan after pancreatic cancer diagnosis, data gathered thus far only relate to pancreatic cancer incidence, and no data are available on its prevalence. Such data are not sufficient to describe racial associations with the etiology, progression, or prevention of the disease.
Tobacco use is clearly the most established preventable risk factor for pancreatic cancer. Research has shown that tobacco use increases an individual's risk of developing pancreatic cancer by about 25 percent. However, the underlying mechanism by which tobacco use contributes to the development of pancreatic cancer remains illusive. Similarly, the data linking pancreatic cancer with industrial exposure to formaldehyde, pesticides, aluminum, and other potential carcinogens are missing. Initial studies investigating a causal relationship between industrial exposures and pancreatic cancer relied heavily on employment records, job titles, union memberships, death certificates, etc. However, these findings have been inconsistent, possibly because of misclassification of exposures in the studies. Therefore, future studies need to focus not only on better defining and assessing the exposure and end points of each study, but also on standardizing the data collecting process and refining the statistical methods used.
It has been estimated that about 10 percent of pancreatic cancer occurs in a familial form and may be linked to six genetic syndromes or variants: p16 mutations and hereditary melanoma; BRCA2 mutations; hereditary nonpolyposis colorectal cancer; hereditary pancreatitis; Peutz-Jeghers syndrome; and ataxia telangiectasia. However, it is likely that yet unrecognized susceptibility genes and gene-environment interactions predispose a subset of the population to pancreatic cancer.
The purpose of this initiative is to promote innovative research across multiple disciplines to better understand the etiology of pancreatic cancer and to promote its early detection, prevention, and treatment. Specific topics of interest include, but are not limited to, the following:
Identification of genetic aberrations (e.g., mutations, epigenetic changes, etc.) or combinations of aberrations and alterations that initiate or promote pancreatic cancer;
Development of experimental models for human pancreatic cancer to facilitate the understanding of molecular carcinogenesis, to help identify promising molecular targets, and to test new preventive/therapeutic strategies;
Exploration of molecular pathways using human cell lines and/or tissues to identify novel targets for prevention or therapeutic development;
Examination of how variations in cells may combine with the microenvironment in the development of pancreatic cancer;
Evaluation of the roles of inflammation, tumor stem cells, energy balance, and biological and chemical agents that contribute to cancer;
Assessment of the roles of HBV, HCV, and Helicobacter pylori (H. pylori) infections in development of cancer;
Identification of markers for early detection of cancer;
Conduct of preclinical studies to identify candidate chemopreventive drug(s) and dietary factors for prevention and to characterize the molecular mechanism(s) of the agent's activity;
Conduct of preclinical studies to identify and characterize candidate biomarkers for pancreatic cancer risk, i.e., factors modifying pancreatic etiologic events and/or exposures (e.g., insulin-like growth factor-1);
Development of early-stage clinical trials in pancreatic cancer prevention and therapy;
Conduct of small exploratory clinical trials with a potential chemopreventive agent (e.g., a farnsyltransferase inhibitor or a statin) assessing response via endoscopic ultrasound or another similar technology;
Conduct of proteomic profiling studies to discriminate among sera of pancreatic cancer case patients, chronic pancreatitis patients, and control subjects to provide initial data on the performance characteristics (sensitivity, specificity, positive predictive value, negative predictive value) of the method in detecting pancreatic neoplasia or other diseases;
Evaluation of serum expression profiles from pancreatic cancer patients collected prospectively and following surgical resection to determine the stability of the diagnostic profiles and demonstrate the utility of this methodology in providing an early marker of pancreatic cancer recurrence;
Assessment of any associations of tumor pathophysiology with tumor development, progression, and preventive/therapeutic response;
Conduct of ancillary imaging studies in pancreatic cancer clinical trials;
Conduct of correlative studies using specimens from multi-institutional prevention and treatment trials to study outcomes;
Conduct of exploratory studies to identify and evaluate biomarkers (with associated assay development) to determine prognosis and predict response to therapy in pancreatic cancer;
Evaluation of combination therapies for pancreatic cancer;
Identification of ‘new' environmental exposures that contribute to pancreatic cancer including adverse energy balance;
Development of a biofluid-based test for pancreatic cancer that can be used in population studies;
Determination of what combination of ‘two hits'—genetic and/or environmental—are needed for pancreatic cancer to develop;
Assessment of the impact of pancreatic cancer on health-related quality of life of patients and their caregivers;
Conduct of pilot surveillance studies and generation of survivorship registries; and
Applicants are encouraged to propose other topics that may help us understand the etiology of pancreatic cancer and provide opportunities to prevent and treat pancreatic cancer.
Section II. Award Information1. Mechanism(s) of Support
This funding opportunity will use the NIH Small Grant (R03) and NIH Exploratory/Developmental Research Grant (R21) individual research project grant award mechanisms.
The NIH Small Research Grant (R03) mechanism should be used for support of pilot and/or feasibility studies for concepts that are sound and justifiable, but not sufficiently developed for the R01 (investigator-initiated research project grant) mechanism. Competing continuation grants will not be accepted. Small grant support may not be used for thesis or dissertation research. Only up to two revisions (amendments) of a previously reviewed R03 grant application may be submitted as defined in NIH policy at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-046.html. Applicants should follow the guidelines published in the NIH Guide for Grants and Contracts at http://grants.nih.gov/grants/guide/pa-files/PA-03-108.html.
The NIH Exploratory/Developmental Research Grant (R21) mechanism is intended to encourage new exploratory and developmental research projects and/or exploration of new hypotheses or strategies. Exploratory/Developmental grant support is for new projects only; competing renewal applications will not be accepted. Only up to two revisions (amendments) of a previously reviewed exploratory/developmental (R21) grant application may be submitted as defined in NIH policy at http://grants.nih.gov/grants/policy/amendedapps.htm. Additional information and guidelines for applications to the R21 mechanism can be found at http://grants.nih.gov/grants/guide/pa-files/pa-03-107.html.
As an applicant, you will be solely responsible for planning, directing, and executing the proposed project.
This funding opportunity uses just-in-time concepts. It also uses the modular budget format described in the PHS 398 application instructions (see http://grants.nih.gov/grants/funding/modular/modular.htm).
The total project period for applications submitted in response to this announcement may not exceed 2 years. These grants are not renewable.
2. Funds Available
Applications received in response to this PA will compete for funds in the general funding pool. No set-aside of funding is available.
The requested funding for individual R03 awards may not exceed $50,000 in direct costs per year for a maximum of 2 years. The requested direct costs for the R21 award may not exceed $100,000 for the first year and $175,000 for the second year.
The anticipated start date for the award is July 2006.
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the NCI provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.
Facilities and administrative costs requested by consortium participants are not included in the direct cost limitation; see NOT-OD-05-004.
Section III. Eligibility Information1. Eligible Applicants
1.A. Eligible Institutions
You may submit (an) application(s) if your organization has any of the following characteristics:
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs.
2. Cost Sharing or Matching
Not applicable
3. Other-Special Eligibility Criteria
Not applicable
1. Address to Request Application Information
The PHS 398 application instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398. For further assistance, contact GrantsInfo; Telephone: (301) 435-0714; Email: GrantsInfo@nih.gov.
Telecommunications for the hearing impaired: TTY 301-451-0088.
2. Content and Form of Application Submission
Applications must be prepared using the most current PHS 398 research grant application instructions and forms. Applications must have a D&B Data Universal Numbering System (DUNS) number as the universal identifier when applying for Federal grants or cooperative agreements. The D&B number can be obtained by calling (866) 705-5711 or through the web site at http://www.dnb.com/us/. The D&B number should be entered on line 11 of the face page of the PHS 398 form.
The title and number of this funding opportunity must be typed on line 2 of the face page of the application form and the YES box must be checked.
Foreign Organizations
Several special provisions apply to applications submitted by foreign organizations:
Proposed research should provide a unique research opportunity not available in the U.S.
3. Submission Dates and Times
Applications must be received on or before the receipt date described below (Section IV.3.A). Submission times are not applicable.
3.A. Receipt, Review and Anticipated Start Dates
Letter of Intent Receipt Dates: Not Applicable
Application Receipt Dates: http://grants.nih.gov/grants/funding/submissionschedule.htm
Peer Review Dates: http://grants.nih.gov/grants/funding/submissionschedule.htm
Council Review Dates: http://grants.nih.gov/grants/funding/submissionschedule.htm
Earliest Anticipated Start Date: http://grants.nih.gov/grants/funding/submissionschedule.htm
Additional Information To Be Available Date (URL Activation Date): Not Applicable
3.A.1. Letter of Intent
Not applicable
3.B. Sending an Application to the NIH
Applications must be prepared using the PHS 398 research grant application instructions and forms as described above. Submit a signed, typewritten original of the application, including the checklist, and five signed photocopies in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier service; non-USPS service)
3.C. Application Processing
Applications must be received on or before the application receipt date(s) described above (Section IV.3.A.). If an application is received after that date, it will be returned to the applicant without review. Upon receipt, applications will be evaluated for completeness by CSR and responsiveness by the National Cancer Institute.
The NIH will not accept any application in response to this funding opportunity that is essentially the same as one currently pending initial review unless the applicant withdraws the pending application. The NIH will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of a substantial revision of an application already reviewed, but such application must include an Introduction addressing the previous critique.
Although there is no immediate acknowledgement of the receipt of an application, applicants are generally notified of the review and funding assignment within 8 weeks.
4. Intergovernmental Review
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm (see also Section VI.3. Reporting).
6. Other Submission Requirements
Plan for Sharing Research Data
Not applicable
Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/index.htm and http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part7.htm#_Toc54600131). Investigators responding to this funding opportunity should include a plan for sharing research resources addressing how unique research resources will be shared or explain why sharing is not possible.
The adequacy of the resource sharing plan and any related data sharing plans will be considered by Program staff of the funding organization when making recommendations about funding applications. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report (PHS 2590, http://grants.nih.gov/grants/funding/2590/2590.htm). See Section VI.3. Reporting.
Section V. Application Review Information1. Criteria
Only the review criteria described below will be considered in the review process.
2. Review and Selection Process
Appropriate scientific review groups convened in accordance with the standard NIH peer review procedures (http://www.csr.nih.gov/refrev.htm) will evaluate applications for scientific and technical merit.
As part of the initial merit review, all applications will:
The following will be considered in making funding decisions:
The goals of NIH supported research are to advance our understanding of biological systems, to improve the control of disease, and to enhance health. In their written critiques, reviewers will be asked to comment on each of the following criteria in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that an application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward.
1. Significance. Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced? What will be the effect of these studies on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
2. Approach. Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
3. Innovation. Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?
4. Investigators. Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)?
5. Environment. Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?
2.A. Additional Review Criteria:
In addition to the above criteria, the following items will continue to be considered in the determination of scientific merit and the priority score:
Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed (see the Research Plan, Section E on Human Subjects in the PHS Form 398).
Inclusion of Women, Minorities and Children in Research: The adequacy of plans to include subjects from both genders, all racial and ethnic groups (and subgroups), and children as appropriate for the scientific goals of the research will be assessed. Plans for the recruitment and retention of subjects will also be evaluated (see the Research Plan, Section E on Human Subjects in the PHS Form 398).
Care and Use of Vertebrate Animals in Research: If vertebrate animals are to be used in the project, the five items described under Section F of the PHS Form 398 research grant application instructions will be assessed.
Biohazards: If materials or procedures are proposed that are potentially hazardous to research personnel and/or the environment, determine if the proposed protection is adequate.
2.B. Additional Review Considerations
Budget: The reasonableness of the proposed budget and the requested period of support in relation to the proposed research. The priority score should not be affected by the evaluation of the budget.
2.C. Sharing Research Data
Data Sharing Plan: Not applicable
2.D. Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (See the NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps/part_ii_5.htm#availofrr and http://www.ott.nih.gov/policy/rt_guide_final.html). Investigators responding to this funding opportunity should include a sharing research resources plan addressing how unique research resources will be shared or explain why sharing is not possible.
Program staff will be responsible for the administrative review of the plan for sharing research resources.
The adequacy of the resource sharing plan will be considered by Program staff of the funding organization when making recommendations about funding applications. Program staff may negotiate modifications of the data and resource sharing plans with the awardee before recommending funding of an application. The final version of the data and resource sharing plans negotiated by both will become a condition of the award of the grant. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report (PHS 2590). See Section VI.3.Reporting.
3. Anticipated Announcement and Award Dates
Not applicable
1. Award Notices
After peer review of the application is completed, the Principal Investigator will also receive a written critique called a Summary Statement.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant. For details, applicants may refer to the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part4.htm).
A formal notification in the form of a Notice of Grant Award (NGA) will be provided to the applicant organization. The NGA signed by the grants management officer is the authorizing document. Once all administrative and programmatic issues have been resolved, the Notice of Grant Award will be generated via email notification from the awarding component to the grantee business official (designated in item 14 on the Application Face Page on the Form PHS 398). If a grantee is not email enabled, a hard copy of the Notice of Grant Award will be mailed to the business official.
Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NGA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See Also Section IV.5. Funding Restrictions.
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the notice of grant award. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm) and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part9.htm).
Awardees will be required to submit the PHS Non-Competing Grant Progress Report, Form 2590 annually (http://grants.nih.gov/grants/funding/2590/2590.htm) and financial statements as required in the NIH Grants Policy Statement.
Section VII. Agency ContactsWe encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research, peer review, and financial or grants management issues:
1. Scientific/Research Contacts:
For cancer control, epidemiology, and survivorship, contact:
Mukesh Verma, Ph.D.
Division of Cancer Control and Population Sciences
National Cancer Institute
6130 Executive Boulevard, EPN Room 5104 , MSC 7324
Bethesda, MD 20892-7324
Rockville, MD 20852 (express/courier service)
Telephone: (301) 594-7344
FAX: (301) 402-4279
Email: vermam@mail.nih.gov
For cancer biology and models, contact:
Judy Mietz, Ph.D.
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard, EPN Room 5028, MSC 7391
Bethesda, MD 20892-7391
Rockville, MD 20852 (express/courier service)
Telephone: (301) 496-9326
FAX: (301) 496-1224
Email: mietzj@mail.nih.gov
For cancer etiology, contact:
Mary Ellen Perry, Ph.D.
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard, EPN Room 5034, MSC 7396
Bethesda, MD 20892-7396
Rockville, MD 20852 (express/courier service)
Telephone: (301) 496-7028
FAX: (301) 402-5034
Email: perryma@mail.nih.gov
For cancer exogenous factors including diet, and cancer prevention contact:
Sharon Ross, Ph.D.
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, EPN Room 3160, MSC 7328
Bethesda, MD 20892-7328
Rockville, MD 20852 (express/courier service)
Telephone: (301) 496-8573
FAX: (301) 480-3925
Email: rosssha@mail.nih.gov
For cancer diagnosis and treatment contact:
Roy Wu , Ph.D.
Division of Cancer Treatment and Diagnosis
National Cancer Institute
6130 Executive Boulevard, EPN Room 7009, MSC 7432
Bethesda, MD 20892-7432
Rockville, MD 20852 (express/courier service)
Telephone: (301) 496-8866
FAX: (301) 480-4663
Email: wur@ctep.nci.nih.gov
For translational research scientific discussion only, and not for grant referral, contact:
Ivan Ding, Ph.D.
Office of Centers, Training and Resources
Specialized Centers of Research Excellence
National Cancer Institute
6116 Executive Boulevard
Room 7036
Bethesda, MD 20892
Rockville, MD 20852 (express/courier service)
Telephone: (301) 496-8528
FAX: (301) 402-5319
Email: dingi@mail.nih.gov
2. Peer Review Contacts:
Direct your questions about peer review issues to:
Referral Officer
National Cancer Institute
Division of Extramural Activities
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 496?3428
FAX: (301) 402-0275
Email: ncirefof@dea.nci.nih.gov
3. Financial or Grants Management Contacts:
Direct your questions about financial or grants management matters to:
Crystal Wolfrey
Team Leader, DCCPS Team
National Cancer Institute
6120 Executive Blvd., EPS Suite 243, MSC 7150
Bethesda, MD 20892-7150
Rockville, MD 20852 (express/courier service)
Telephone: (301) 496-8634
FAX: (301) 496-8601
Email: wolfreyc@mail.nih.gov
Required Federal Citations
Use of Animals in Research:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (phase I); efficacy studies (Phase II); efficacy, effectiveness and comparative trials (Phase III). Monitoring should be commensurate with risk. The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants (NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (http://grants.nih.gov/grants/policy/data_sharing).
Investigators should seek guidance from their institutions, on issues related to institutional policies and local IRB rules, as well as local, State and Federal laws and regulations, including the Privacy Rule. Reviewers will consider the data sharing plan but will not factor the plan into the determination of the scientific merit or the priority score.
Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see http://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh-Dole Act (see the NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/index.htm). All investigators submitting an NIH application or contract proposal, beginning with the October 1, 2004, receipt date, are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. This will permit other researchers to benefit from the resources developed with public funding. The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.
Inclusion of Women And Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the new PHS Form 398; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children as Participants in Clinical Research:
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them.
All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (http://grants.nih.gov/grants/funding/children/children.htm).
Required Education on the Protection of Human Subject Participants:
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel. The policy is available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov/). It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s) to be used in the proposed research. Applications that do not provide this information will be returned without review.
Public Access to Research Data through the Freedom of Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide public access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are (1) first produced in a project that is supported in whole or in part with Federal funds and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this PA in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.
Standards for Privacy of Individually Identifiable Health Information:
The Department of Health and Human Services (DHHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information", the "Privacy Rule", on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site.
Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This PA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and Regulations:
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas. The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt. Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged. The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50 percent of their time (at least 20 hours per week based on a 40 hour week) for two years to the research. For further information, please see: http://www.lrp.nih.gov/.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |